Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
2
Recruiting, industry sponsors, Endocrinology and women's health, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed105
2 trials
Showing 1 to 2, recently updated first.
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeRecruiting
RECORDATI GROUPIndustry
NCT07247162 · 63 participants (planned) · Start Aug 26, 2026 · Primary completion May 2028
Drug: Osilodrostat; Placebo · For: Hypertension; Hypercortisolemia; Cushing Syndrome
Sites: Jacksonville, Florida; Canton, Ohio; Weslaco, Texas
Bio Meds Pharmaceutica LtdaIndustry
NCT06543550 · 70 participants (planned) · Start Jul 30, 2024 · Primary completion Mar 2027
Drug: Implantable gestrinone; Oral Dienogest · For: Endometriosis
Sites: Campina Grande, Brazil; Rio de Janeiro, Brazil; São José dos Campos, Brazil · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.